Breaking News Instant updates and real-time market news.

RGLS

Regulus

$0.36

0.02 (5.88%)

, SNY

Sanofi

$41.84

-0.65 (-1.53%)

07:39
07/10/18
07/10
07:39
07/10/18
07:39

Regulus downgraded to Neutral at Wedbush

As previously reported, Wedbush analyst Liana Moussato downgraded Regulus (RGLS) to Neutral from Outperform after he extended developmental timelines due to partnership restructuring with Sanofi (SNY) pausing clinical enrollment for RG-012 and unexpected mouse toxicity observations delaying clinical progress for RGLS4326. The analyst also lowered his price target on Regulus shares to $1 from $3.

RGLS

Regulus

$0.36

0.02 (5.88%)

SNY

Sanofi

$41.84

-0.65 (-1.53%)

  • 12

    Jul

  • 20

    Oct

  • 28

    Oct

  • 28

    Jan

  • 22

    Mar

RGLS Regulus
$0.36

0.02 (5.88%)

01/05/18
01/05/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Becton Dickinson (BDX) initiated with an Overweight at KeyBanc. 2. Syndax (SNDX) initiated with a Buy at B. Riley FBR. 3. Sutherland Asset Management (SLD) initiated with an Outperform at JMP Securities. 4. Nike (NKE) was assumed with a Buy at Buckingham while Under Armour (UA, UAA) was assumed with a Neutral. 5. Regulus (RGLS) initiated with an Outperform at Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/18
RILY
03/27/18
INITIATION
Target $1
RILY
Neutral
Regulus initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Regulus Therapeutics with a Neutral rating and $1 price target. The analyst believes the company is facing uncertainty in orphan kidney disease.
07/06/18
WELS
07/06/18
NO CHANGE
Target $0.5
WELS
Market Perform
Regulus price target lowered to 50c from $1.50 at Wells Fargo
Wells Fargo analyst Jim Birchenough lowered his price target for Regulus Therapeutics to the company's approximate cash level of 50c following the interruption of the Phase 1 study of anti-miR therapeutic RGLS4326 in autosomal dominant polycystic kidney disease due to unexpected preclinical toxicity and need for additional preclinical work. With "limited cash runway and continued unpredictable effects of its anti-miR therapeutic candidates," the analyst sees continued overhang and need to monetize earlier pipeline assets to support a recovery in shares of Regulus. He keeps a Market Perform rating on the name.
07/10/18
WEDB
07/10/18
DOWNGRADE
WEDB
Neutral
Regulus downgraded to Neutral from Outperform at Wedbush
SNY Sanofi
$41.84

-0.65 (-1.53%)

05/23/18
LEHM
05/23/18
NO CHANGE
Target $290
LEHM
Underweight
Regeneron product concentration remains big risk, says Barclays
Barclays analyst Geoff Meacham says his analysis suggests Eylea concentration remains a big risk for Regeneron Pharmaceuticals (REGN). A scenario analysis shows the company's adjusted earnings is sensitive to even modest changes to U.S. Eylea sales versus any product under the Sanofi (SNY) joint venture, namely Dupixent, Praluent, and Kevzara, Meacham tells investors in a research note. The analyst reiterates an Underweight rating on Regeneron with a $290 price target.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/02/18
PIPR
07/02/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron has 'substantial' opportunity for Q2 upside, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that with Dupixent script trends indicated up almost 30% quarter-over-quarter, Regeneron's (REGN) opportunity for Q2 upside is "substantial." Further, Regeneron and Sanofi (SNY) over the weekend raised the list price by 3% for the drug's first ever price increase, Raymond tells investors in a research note. He thinks Dupixent remains well positioned to outperform expectations "this quarter and beyond." The analyst maintains an Overweight rating on Regeneron with a $450 price target.

TODAY'S FREE FLY STORIES

OPGN

OpGen

$1.91

-0.01 (-0.52%)

17:45
10/15/18
10/15
17:45
10/15/18
17:45
Earnings
OpGen says preliminary Q3 revenue $550K vs. $750K in Q317 »

Total preliminary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPX

Tempur Sealy

$47.87

0.03 (0.06%)

, SHLD

Sears

$0.31

-0.0901 (-22.52%)

17:44
10/15/18
10/15
17:44
10/15/18
17:44
Hot Stocks
Tempur Sealy: Sears represented less than 5% of company's global net sales »

In connection with the…

TPX

Tempur Sealy

$47.87

0.03 (0.06%)

SHLD

Sears

$0.31

-0.0901 (-22.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$115.95

0.71 (0.62%)

17:42
10/15/18
10/15
17:42
10/15/18
17:42
Hot Stocks
SPDR Gold Trust rise to 748.76MT from 744.64MT »

This is the 2nd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IGC

India Globalization Capital

$5.30

0.35 (7.07%)

17:35
10/15/18
10/15
17:35
10/15/18
17:35
Syndicate
Breaking Syndicate news story on India Globalization Capital »

India Globalization…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RWLK

ReWalk Robotics

$0.81

-0.0038 (-0.47%)

17:34
10/15/18
10/15
17:34
10/15/18
17:34
Syndicate
Breaking Syndicate news story on ReWalk Robotics »

ReWalk Robotics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$123.59

0.12 (0.10%)

17:34
10/15/18
10/15
17:34
10/15/18
17:34
Initiation
Zimmer Biomet initiated  »

Zimmer Biomet initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 26

    Oct

RIO

Rio Tinto

$49.54

0.34 (0.69%)

17:34
10/15/18
10/15
17:34
10/15/18
17:34
Hot Stocks
Breaking Hot Stocks news story on Rio Tinto »

Rio Tinto sees Pilbara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$249.10

0.64 (0.26%)

17:33
10/15/18
10/15
17:33
10/15/18
17:33
Initiation
Teleflex initiated  »

Teleflex initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

RIO

Rio Tinto

$49.54

0.34 (0.69%)

17:33
10/15/18
10/15
17:33
10/15/18
17:33
Hot Stocks
Rio Tinto reports Q3 Pilbara iron ore output 82.5M tons, down 3% from last year »

Pilbara iron ore…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYK

Stryker

$169.42

-1.66 (-0.97%)

17:33
10/15/18
10/15
17:33
10/15/18
17:33
Initiation
Stryker initiated  »

Stryker initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

MDT

Medtronic

$93.81

-0.85 (-0.90%)

17:32
10/15/18
10/15
17:32
10/15/18
17:32
Initiation
Medtronic initiated  »

Medtronic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$238.05

-10.84 (-4.36%)

17:31
10/15/18
10/15
17:31
10/15/18
17:31
Hot Stocks
Adobe says it is expanding creative cloud to non-professionals »

Says over the last few…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

HRC

Hill-Rom

$87.26

-1.04 (-1.18%)

17:30
10/15/18
10/15
17:30
10/15/18
17:30
Initiation
Hill-Rom initiated  »

Hill-Rom initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

EW

Edwards Lifesciences

$141.95

-1.44 (-1.00%)

17:29
10/15/18
10/15
17:29
10/15/18
17:29
Initiation
Edwards Lifesciences initiated  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CNMD

CONMED

$73.17

0.73 (1.01%)

17:28
10/15/18
10/15
17:28
10/15/18
17:28
Initiation
CONMED initiated  »

CONMED initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

TTOO

T2 Biosystems

$5.30

0.17 (3.31%)

17:27
10/15/18
10/15
17:27
10/15/18
17:27
Syndicate
Breaking Syndicate news story on T2 Biosystems »

T2 Biosystems files $100M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$36.43

-0.56 (-1.51%)

17:26
10/15/18
10/15
17:26
10/15/18
17:26
Initiation
Boston Scientific initiated  »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BDX

Becton Dickinson

$238.38

-4.33 (-1.78%)

17:25
10/15/18
10/15
17:25
10/15/18
17:25
Initiation
Becton Dickinson initiated  »

Becton Dickinson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BAX

Baxter

$70.88

-0.39 (-0.55%)

17:24
10/15/18
10/15
17:24
10/15/18
17:24
Initiation
Baxter initiated  »

Baxter initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 31

    Oct

CRMD

CorMedix

$2.15

-0.12 (-5.29%)

17:23
10/15/18
10/15
17:23
10/15/18
17:23
Syndicate
Breaking Syndicate news story on CorMedix »

CorMedix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVNS

Avanos

$60.02

0.59 (0.99%)

17:22
10/15/18
10/15
17:22
10/15/18
17:22
Initiation
Avanos initiated  »

Avanos initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$68.72

-0.62 (-0.89%)

17:19
10/15/18
10/15
17:19
10/15/18
17:19
Initiation
Abbott initiated  »

Abbott initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SBBX

SB One Bancorp

$24.00

-0.27 (-1.11%)

17:19
10/15/18
10/15
17:19
10/15/18
17:19
Hot Stocks
Breaking Hot Stocks news story on SB One Bancorp »

EJF Capital reports 5.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HQCL

Hanwah Q Cells

$8.20

-0.13 (-1.56%)

17:07
10/15/18
10/15
17:07
10/15/18
17:07
Hot Stocks
Hanwah Q Cells up 8.5% after agreeing to be acquired by Hanwha Solar »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBRX

Moleculin Biotech

$1.38

-0.005 (-0.36%)

17:06
10/15/18
10/15
17:06
10/15/18
17:06
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.